GlassScriptPhysician profile
Raul G Santos
NPI 1124008297
$763.84
in general payments reported to CMS, 2019-2025
11 companies · $26.60 in 2025
The $26.60 reported for 2025 was less than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
See the full distribution for Nephrology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $142 · 2020: $11.13 · 2021: $72.70 · 2022: $91.38 · 2023: $97.06 · 2024: $323 · 2025: $26.60.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $420 · Education: $26.27.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $420.47 |
| Education | $26.27 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $180.89 | 2020-2024 | Farxiga |
| Avenu Medical INC. | $141.89 | 2019 | |
| Aurinia Pharma U.S., INC. | $114.30 | 2024 | Lupkynis |
| Baxter Healthcare | $97.06 | 2023 | Renal - Pd |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.62 | 2024 | Jardiance |
| Abbott Laboratories | $49.87 | 2022 | |
| Bayer Healthcare Pharmaceuticals INC. | $39.02 | 2022 | |
| Alnylam Pharmaceuticals INC. | $25.49 | 2021 | |
| Fresenius USA Marketing, INC. | $24.94 | 2025 | Velphoro |
| Akebia Therapeutics INC | $24.61 | 2024 | Vafseo |
| Travere Therapeutics, INC. | $4.15 | 2022-2025 | Filspari |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Raul Santos listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.